Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
72.00
-0.68 (-0.94%)
Nov 13, 2026, 4:00 PM EST - Market closed

Monopar Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-20.6-13.72-15.59-8.4-10.52-9.1
Loss (Gain) From Sale of Investments
-2.62-0.72-0.01---
Stock-Based Compensation
6.274.841.141.91.641.47
Other Operating Activities
--4.55---
Change in Accounts Payable
1.010.390.51-1.331.480.4
Change in Other Net Operating Assets
-0-2.992.99-0.020.17-0.09
Operating Cash Flow
-15.95-12.2-6.4-7.86-7.23-7.32
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Investment in Securities
-58.19-63.45-14.344.93-4.92-
Investing Cash Flow
-58.19-63.45-14.344.93-4.92-

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
0.81127.7159.42.070.1111.28
Repurchase of Common Stock
-1.77-36.13-0.1-0.05-0.08-0.06
Other Financing Activities
------0.34
Financing Cash Flow
-0.9691.5759.292.030.0310.88

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.060.10-0.02-00
Net Cash Flow
-75.0416.0238.55-0.92-12.123.57

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-9.4-8.2-5.48-5.01-3.22-3.99
Unlevered Free Cash Flow
-9.4-8.2-5.48-5.01-3.22-3.99

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
1-2.613.5-1.351.650.32
SEC Filings: 10-K · 10-Q